Bilateral Essential Tremor Treatment With Gamma Knife

Recruiting Phase 2 Phase 3 Interventional Study
Essential Tremor
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 2/3
Study type
Interventional
Purpose
Treatment
Participants needed
50 (estimated)
Sponsor
Université de Sherbrooke · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Combined Phase II/III, multi-center, prospective, single-blinded trial. Ten (10) patients with essential tremor who previously underwent successful and uncomplicated GK thalamotomy for essential tremor will undergo a contralateral treatment. The incidence of side effects will be determined at 3 months postoperatively, graded per the CTCAE v5 and analyzed by a data safety monitoring board. Upon su…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Patients must be ≥ 18 years * The patient has a primary diagnosis of ET or ET plus confirmed by a movement disorder neurologist; * The patient previously underwent a GK thalamotomy (\> 12 months ago); * The tremor on the untreated side negatively impacts the patients' quality …
Contacts

Christian Iorio-Morin

819-346-1110

christian.iorio-morin@usherbrooke.ca

CONTACT